DrugPatentWatch Database Preview
Details for Patent: 7,223,440
Which drugs does patent 7,223,440 protect, and when does it expire?
Patent 7,223,440 protects BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in two NDAs.
This patent has twenty-one patent family members in fourteen countries.
Summary for Patent: 7,223,440
| Title: | Residual solvent extraction method and microparticles produced thereby |
| Abstract: | Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step. |
| Inventor(s): | Rickey; Michael E. (Loveland, OH), Ramstack; J. Michael (Lunenburg, MA), Kumar; Rajesh (Marlborough, MA) |
| Assignee: | Alkermes, Inc. (Cambridge, MA) |
| Application Number: | 11/312,371 |
|
Patent Claim Types: see list of patent claims | Formulation; Process; Use; |
Drugs Protected by US Patent 7,223,440
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | BYDUREON | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-001 | Jan 27, 2012 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| Astrazeneca Ab | BYDUREON PEN | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-002 | Feb 28, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| Astrazeneca Ab | BYDUREON BCISE | exenatide | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 209210-001 | Oct 20, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,223,440
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 501711 | Start Trial | |||
| Canada | 2454027 | Start Trial | |||
| Cyprus | 1112348 | Start Trial | |||
| Germany | 60239469 | Start Trial | |||
| Denmark | 1420762 | Start Trial | |||
| European Patent Office | 1420762 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
